Abstract: The bone-modifying agents （BMAs）， including the bisphosphonates （BPs） and the monoclonal antibody denosumab which was approved by FDA in 2010， have a long established role in the management of osteoporosis， hypercalcemia of malignancy and bone metastases from malignant tumors. In recent years， the use of the agents such as the medication time， the usage and side effects has certain progress and controversy. In this review we summarize the development of bone-modifying agents for the treatment of bone metastases in breast cancer.